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Abstract: BACKGROUND Bevacizumab is frequently used in the treatment of recurrent WHO grade II
and III glioma, but without supporting evidence from randomised trials. Therefore, we assessed the use
of bevacizumab in patients with first recurrence of grade II or III glioma who did not have 1p/19q co-
deletion. METHODS The TAVAREC trial was a randomised, open-label phase 2 trial done at 32 centres
across Europe in patients with locally diagnosed grade II or III glioma without 1p/19q co-deletion, with
a first and contrast-enhancing recurrence after initial radiotherapy or chemotherapy, or both. Previous
chemotherapy must have been stopped at least 6 months before enrolment and radiotherapy must have
been stopped at least 3 months before enrolment. Random group assignment was done electronically
through the European Organisation for Research and Treatment of Cancer web-based system, stratified
by a minimisation procedure using institution, initial histology (WHO grade II vs III), WHO performance
status (0 or 1 vs 2), and previous treatment (radiotherapy, chemotherapy, or both). Patients were assigned
to receive either temozolomide (150-200 mg/m, orally) monotherapy on days 1-5 every 4 weeks for a
maximum of 12 cycles, or the same temozolomide regimen in combination with bevacizumab (10 mg/kg,
intravenously) every 2 weeks until progression. The primary endpoint was overall survival at 12 months
in the per-protocol population. Safety analyses were done in all patients who started their allocated
treatment. The study is registered at EudraCT (2009-017422-39) and ClinicalTrials.gov (NCT01164189),
and is complete. FINDINGS Between Feb 8, 2011, and July 31, 2015, 155 patients were enrolled and
randomly assigned to receive either monotherapy (n=77) or combination therapy (n=78). Overall survival
in the per-protocol population at 12 months was achieved by 44 (61% [80% CI 53-69]) of 72 patients
in the temozolomide group and 38 (55% [47-69]) of 69 in the combination group. The most frequent
toxicity was haematological: 17 (23%) of 75 patients in the monotherapy group and 25 (33%) of 76
in the combination group developed grade 3 or 4 haematological toxicity. Other than haematological
toxicities, the most common adverse events were nervous system disorders (59 [79%] of 75 patients in
the monotherapy group vs 65 [86%] of 76 in the combination group), fatigue (53 [70%] vs 61 [80%]), and
nausea (39 [52%] vs 43 [56%]). Infections were more frequently reported in the combination group (29
[38%] of 76 patients) than in the monotherapy group (17 [23%] of 75). One treatment-related death was
reported in the combination group (infection after intratumoral haemorrhage during a treatment-related
grade 4 thrombocytopenia). INTERPRETATION We found no evidence of improved overall survival
with bevacizumab and temozolomide combination treatment versus temozolomide monotherapy. The
findings from this study provide no support for further phase 3 studies on the role of bevacizumab in this
disease. FUNDING Roche Pharmaceuticals.
DOI: https://doi.org/10.1016/S1470-2045(18)30362-0
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-153714
Journal Article
Accepted Version
Originally published at:
van den Bent, Martin J; Klein, Martin; Smits, Marion; et al; Weller, Michael (2018). Bevacizumab and
temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion
(TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncology, 19(9):1170-1179.
DOI: https://doi.org/10.1016/S1470-2045(18)30362-0
2
1 
 
 
 
Randomized phase II trial on the addition of bevacizumab to temozolomide in first recurrence 1p/19q 
intact WHO grade II and III astrocytoma: the EORTC TAVAREC trial. 
 
 
Prof Martin J. van den Bent1 MD,  Martin Klein2 PhD,  Prof Marion Smits3 MD, Jaap C. Reijneveld2 MD, 
Pim J. French1 PhD, Prof Paul  Clement4 MD, Filip .Y.F. de Vos5 MD, Antje Wick6 MD, Paul J. 
Mulholland7 MD, MD, Prof Martin J.B. Taphoorn8 MD, Joanne Lewis9 MD, Prof Michael Weller10 MD, 
Prof Olivier L Chinot11 MD, Prof Johan M. Kros12 MD, Iris  de Heer1 Tina Verschuere13,  Corneel Coens13 
MSc, Vassilis. Golfinopoulos13MD,  Thierry  Gorlia13 PhD,  Ahmed Idbaih14 MD  
1The Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands;  
2Brain Tumor Center and Department of Medical Psychology, VU University Medical Center, 
Amsterdam, the Netherlands 
3Dept of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam the Netherlands,  
4 Department of Oncology, KU Leuven and Department of General Medical Oncology, UZ Leuven, 
Leuven Cancer Institute 
6 Dept Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the 
Netherlands 
6 Neurology Clinic, University of Heidelberg, National Center for Tumor Diseases 
Heidelberg, Germany 
7
 Dept Medical Oncology, UCLH, London, United Kingdom 
8
 Dept Neurology, MC Haaglanden, the Hague, the Netherlands  
9
 Freeman Hospital, Newcastle, United Kingdom, 
10 Department of Neurology and Brain Tumor Center, University Hospital and University of 
 Zurich,  Zurich, Switzerland 
11 Neuro-Oncology division, Aix-Marseille University, AP-HM, Marseille, France 
12 Dept Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands 
13 EORTC Headquarters, Brussels Belgium 
14 Sorbonne Université, ICM, Inserm, CNRS, AP-HP, Hôpital Pitié-Salpêtrière, Service de Neurologie 2-
Mazarin, F-75013 Pars, France  
 
 
2 
 
Corresponding author:  
M J van den Bent 
The  Brain Tumor Center at Erasmus MC Cancer Institute 
Dr Molewaterplein 40 
3015 GD RotterdamThe Netherlands 
Tel +31 10 7041415 
Fax +31 10 7041031 
e-mail m.vandenbent@erasmusmc.nl 
 
Keywords: astrocytoma, bevacizumab, temozolomide, recurrent, IDH, MGMT, 1p/19q codeletion
3 
 
 
Abstract  
Background: Bevacizumab is frequently used in recurrent WHO grade II and III glioma, but this use is 
without evidence from randomized trials. We evaluated the use of bevacizumab in grade II and III 
glioma without 1p/19q co-deletion at first recurrence. 
Methods: The TAVAREC trial (NCT01164189) is a randomized, open label phase II study in locally 
diagnosed 1p/19q non-codeleted grade II or III glioma, with a first and contrast-enhancing recurrence 
after initial radiotherapy and/or chemotherapy. Patients were stratified by a minimization procedure 
using institution, initial histology (grade II or III), WHO performance status (0 or 1 versus 2) and prior 
treatment (radiotherapy, chemotherapy, both). Patients were electronically randomized through the 
EORTC web-based system.  Prior chemotherapy was allowed provided patients were at least 6 
months off treatment. Patients were treated with either 150-200mg/m2 temozolomide day 1-5 every 
4 weeks for a maximum of twelve cycles, or with the same temozolomide regimen in combination 
with bevacizumab 10 mg/kg every 2 weeks until progression. Response, Health Related Quality of 
Life (HRQoL, using the EORTC QOL C30/BN20 questionnaire) and neurocognitive functioning (NCF) 
using a standardized test battery with Hopkins Verbal Learning, Trail Making test A/B and Controlled 
Oral Word Association were evaluated every 3 months. Primary endpoint was the Overall Survival 
(OS) rate at 12 months (OS12) in the intent-to-treat population. Tumor samples were centrally 
analyzed for MGMT status (Illumina Infinium Methylation EPIC BeadChip) and IDH1/2 hotspot 
mutations. This report represents the full analysis of the study. 
Findings: Between 8/2/2011 and 31/7/2015, 155 patients were randomized; median age was 44 
years, 101 of 131 (77%) tested tumors showed an IDH mutation (IDHmt), 27% of patients had 
received prior chemotherapy. OS12 was 61% in the temozolomide arm and 55% in the combination 
arm, with overlapping OS and progression free survival (PFS) Kaplan Meier curves. The most frequent 
toxicity was hematological, 17 (23%) patients in the monotherapy arm and 25 (33%) in the 
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combination arm developed grade 3 or 4 hematological toxicity. Infections  were more frequently 
reported in the bevacizumab arm 29:76 versus 17:75 in the control arm). One treatment related 
death was reported in the combination arm (intratumoral hemorrhage).  
Conclusions: In this randomized phase II in recurrent grade II and III 1p/19q intact gliomas no 
evidence was observed of improved OS, PFS, neurocognitive functioning or quality of life of the the 
addition of bevacizumab to temozolomide; regardless of IDH mutational status. This study provides 
no support for further phase III studies to the role of bevacizumab in this disease.  
The study was supported by Roche pharmaceuticals. 
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Research in Context 
Evidence before this study: Uncontrolled studies on recurrent glioblastoma reported high response 
rates and progression free survival rates to bevacizumab, and suggested improved overall survival. 
Prior to the study, a Pubmed literature search was conducted with the search parameters 
bevacizumab, astrocytoma and oligodendroglioma ;within the time interval January 2007 (initial 
reports on glioblastoma) and August 2009 (drafting of the protocol). Only uncontrolled 
retrospective reports on the use of bevacizumab in recurrent grade III tumors were identified, that 
suggested similar response rates in comparison to glioblastoma. No properly controlled studies are 
available on bevacizumab in grade II and III glioma. 
Added value of this study. This study shows that adding bevacizumab to temozolomide in patients 
with recurrent grade II and III 1p/19q intact anaplastic glioma does not improve outcome, 
surprisingly also not with respect to response rate, progression free survival, quality of life or 
cognition. 
Implications of all the available evidence. There is no role for adding bevacizumab to temozolomide 
in recurrent 1p/19q intact grade II and III glioma. With a more broader perspective,  the now 
available trial results show that adding bevacizumab to standard of care does not improve overall 
survival in gliomas regardless of grade.
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Introduction 
Currently, the standard of care of newly diagnosed WHO grade II and III glioma consists of surgery as 
extensive as safely possible, followed by combinations of chemotherapy and radiotherapy once post-
operative treatment is indicated.(1) Despite the much better prognosis of grade II and grade III 
glioma patients in comparison to glioblastoma patients, following initial treatment eventually all 
grade II and III glioma patients will relapse. At that time prognosis is poor, especially  in tumors that 
show evidence of increased grade of malignancy and for many patients chemotherapy is the only 
remaining treatment option. Studies show that  40-60% of these patients respond to chemotherapy, 
with patients with combined 1p/19q loss responding more frequently and with longer duration.(2-5) 
At the time of relapse, these tumors often show an increased growth rate and the development of 
enhancement and edema. Histopathologically, these tumors present as glioblastoma showing 
endothelial proliferation and necrosis. Thus, at this disease stage angiogenesis plays a role, 
suggesting a potential role for angiogenesis inhibitors.  Following the initial favorable observations on 
the use of bevacizumab in recurrent glioblastoma with reports that described high clinical and 
radiological response rates and promising progression free survival (PFS) rates, several retrospective 
and uncontrolled reports reported on bevacizumab in recurrent grade II and III glioma.(6-9)  Because 
of these favorable observations, we decided to evaluate the use of bevacizumab in recurrent grade II 
and grade III glioma in a controlled study. In view of occurrence of pseudo-responses in bevacizumab 
treated glioblastoma questioning the usefulness of PFS  we selected overall survival (OS) at 12 
months as the primary endpoint.(10-12) To avoid a too heterogeneous patient population we 
included only patients without 1p/19q co-deletion. At the time of study initiation the prognostic role 
of IDH mutations and especially the worse prognosis of IDH wild type tumors was not fully 
clear.(13;14) Once the pivotal role of IDH mutations in the genesis of grade II and III glioma was 
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established, the protocol was amended to allow a prospectively defined subgroup analysis based on 
IDH mutational status.   
Material and methods 
Study design and participants 
The TAVAREC study was designed as a two-arm open-label randomized multicenter study, to assess 
the activity of bevacizumab in combination with temozolomide  and of temozolomide alone. Eligible 
were patients 18 years of age or older and with a WHO performance status 0-2, with a first 
recurrence of a locally diagnosed grade II or grade III glioma according to the WHO 2007 glioma 
classification at first diagnosis and without 1p/19q co-deletion, following radiotherapy with or 
without chemotherapy and relapsing more than three months after the end of radiotherapy. High 
dose radiotherapy (over 65 Gy) was not allowed unless the recurrence was histologically proven. 
Only procarbazine/CCNU/vincristine (PCV) or temozolomide were allowed as prior chemotherapy 
and patients needed to be more than 6 months off chemotherapy before progression. Prior 
treatment with anti-angiogenic treatments was not allowed. Surgery at the time of the recurrence 
was allowed, in which case residual and measurable disease after surgery was not required but 
histology must have confirmed the presence of tumor . Non-operated patients needed to have an 
enhancing recurrence with bi-dimensionally measurable disease (minimal diameters enhancing 
lesion of 10 mm) on the MRI scan, with stable or decreasing dose of steroids prior for 7 days to the 
baseline MR scan.  Patients needed to have adequate hematological, renal and hepatic function. No 
other diseases interfering with follow-up including other malignancies were allowed, except for any 
previous malignancy which was treated with curative intent more than 5 years prior to 
randomization, and except for adequately controlled limited basal cell carcinoma of the skin, 
squamous carcinoma of the skin or carcinoma in situ of the cervix. Other exclusion criteria included 
presence of cardiovascular disorders, significant vascular disease within 6 months prior to 
randomization, prior history of hypertensive crisis or hypertensive encephalopathy, inadequately 
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controlled hypertension (defined as systolic blood pressure >150 mm Hg and/or diastolic blood 
pressure >100 mm Hg); any thrombotic or hemorrhagic event, a history of active gastroduodenal 
ulcer(s) or a history of abdominal fistula as well as non-gastointestinal fistula, gastrointestinal 
perforation or intra-abdominal abscess within the 6 months prior to inclusion. 
 
Randomisation and masking 
Patients were randomized and stratified by a minimization procedure based on the variance method 
with semi-random assignment as implemented by Freedman and White (1976).(15) In order to 
reduce treatment allocation predictability, a random allocation component was included in order to 
ensure an additional 15% of completely random assignments.  Stratification factors were institution, 
initial histology (WHO grade II v ersus grade III), WHO performance status (0, 1 vs 2) and prior 
treatment (radiotherapy alone, temozolomide or PCV alone, vs combined chemo-irradiation with 
temozolomide. Patients were registered by the treating institutions and electronically randomized 
through the EORTC web-based ORTA system (http://www.eortc.org/investigators/). An A'Hern one 
stage (one-sided) testing procedure was used, assuming an OS 12 of 50% was inadequate while 65% 
warranting further exploration. With alfa and beta set at 0.10, with a 1:1 randomization, the required 
sample size was 72 eligible patients in each treatment arm for a total of 144 eligible patients. The 
decision rule for activity was to be performed amongst the first 72 eligible patients enrolled in the 
bevacizumab – temozolomide arm and the temozolomide alone arm separately (requiring 42 
patients or more to be alive at 12 months to call a treatment a ‘success’). 
Procedures 
Patients were randomized to a) temozolomide 200 mg/m2 on day 1-5 every 4 weeks for a maximum 
of 12 cycles, with patients having received prior chemotherapy starting at 150 mg/m2 with dose 
escalation to 200 mg/m2 in case of no or minimal toxicity; or to b) the same temozolomide regimen 
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combined with 10 mg/kg bevacizumab intravenously every 2 weeks until progression. Treatment was 
discontinued at progression, unacceptable toxicity or patient refusal. Dose reductions were made as 
described elsewhere. (16;17) One treatment cycle was defined as a period of 4 weeks. 
The baseline evaluation included a standardized MRI protocol (consisting of T2-weighted and pre- 
and post-contrast T1-weighted imaging), a HRQoL questionnaire (the generic EORTC QLQC30 
questionnaire in combination with the BN20 brain-cancer specific module), neurocognitive testing 
(using a standardized psychometric assessment: Hopkins Verbal Learning Test-Revised (HVLT-R; free 
recall, delayed recall and delayed recognition); Trail Making Test (A and B) and Controlled Oral Word 
Association (COWA) as described elsewhere)(18), full clinical and neurological evaluation, ECG, as 
well as complete blood count, blood chemistry and urinanalysis. Bevacizumab treated patients were 
evaluated for vital signs, adverse events, hematology and urine dipstick exam every 2 weeks. All 
patients were evaluated every 4 weeks for vital signs, adverse events, and blood examinations. Every 
3 months, neurological evaluation, MRI scanning, HRQoL evaluation and neurocognitive testing was 
performed.  
Response assessment was done according to the RANO criteria.(11) In case of equivocal PD (target or 
non-target), treatment could continue until the next assessment, but if PD was confirmed at the next 
follow-up, the earlier date was used as the date of progression. All decisions on the assessment and 
interpretation of disease status (including 1p/19q assessment) were done locally, with preplanned 
central review afterwards.  
At the time of study analysis central pathology review and molecular testing was performed (JMK, 
PF). Assessment of  MGMT promoter methylation status was done using the Infinium 
MethylationEPIC BeadChip (Illumina, San Diego, Ca). .(19;20) The MGMT methylation status was 
determined by the MGMT-STP27 model using the mgmtstp27 R package (github.com) .(21) IDH1 and 
2 mutations were determined using Sanger sequencing.  In case of inconclusive sequencing results 
(e.g. due to poor DNA quality or insufficient quantity) we performed  immunohistochemistry using 
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IDH1R132H-specific antibodies (Dianova, Germany, see Capper, ANP 2009). Positive staining on 
immunohistochemistry was scored as IDHmt, negative staining was scored as indeterminate IDH 
status as other, non-R132H-mutations, may be present. 
 
Outcomes 
The primary endpoint was probability of survival at 12 months (OS12. Secondary endpoints were best 
overall response, objective (partial PR and complete CR) response rate and duration of response, 
progression free survival (PFS) distribution and at 6 and 12 months; overall survival (OS) distribution 
and at 24 months (Kaplan Meier Estimates); safety profile;  and patient oriented criteria: 
clinical/neurological deterioration free survival, steroid use, quality of life (by patients and 
caregivers) and development of cognitive deterioration..  
 
 
Statistical analysis 
OS was calculated from the date of randomization to the date of death from any cause. Patients still 
alive or lost to follow-up were censored at last follow-up visit date.  The percentage of patients alive 
at 1 year is presented with binomial 80% confidence intervals (CI [,]). Both response and PFS were 
defined  according to RANO criteria.(11)The objective response rates and other rates are reported 
with binomial 95% CI (,). PFS was defined as the time from randomization to the date of first 
progression or death, whichever came first. Patients were censored at the last follow-up visit without 
evidence of progression or at the date of starting a new anti-tumoral therapy before progression.  
The Kaplan Meier technique was used to compute estimate of OS and PFS with 95% CI (,)The Cox 
proportional hazard model was used  in multivariable analysis to assess the treatment effect adjusted 
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by the stratification factor at randomization (except institution), to infere the treatment by factor 
interaction term in predictive factor analysis and to identify independent prognostic factors. The 
hazard ratios were presented with 95% CI (,). For prognostic model building, baseline clinical and 
molecular factors were jointly screened. Stepwise selection method was used at 5 % significance and 
the bootstrap technique was employed to estimate the probability of inclusion of factors in the Cox 
model. A probability of inclusion of 60% or more was considered appropriate. Models discrimination 
was measured by the Harrel’s C-index, a C-index larger than 60% was considered a minimum.(22;23) 
Relative dose intensity (RDI) was calculated as the administered dose per time as delivered divided 
by the planned dose per planned time of delivery. Primary efficacy analyses were performed in the 
per protocol population defined as all eligible patients who started their allocated treatment. No 
direct comparison was performed in this population. As sensitivity analysis, formal comparisons of 
PFS and OS were performed in the intent to treat population. RDI and safety analyses were 
performed in the safety population defined as all patients who started allocated treatment. For all 
statistical analyses, SAS version 9.4 (Copyright (c) 2002-2012 by SAS Institute Inc., Cary, NC, USA. All 
Rights Reserved) was used. 
HRQoL assessment: HRQoL data were scored according to the algorithm described in the EORTC 
scoring manual.(24) Herein are responses aggregated and transformed into a linear scale that ranged 
from 0 to 100, in which a higher score represented a higher level of functioning (function scales) or a 
higher level of symptoms (symptom scales). If at least half of the items in the scale were completed, 
the scale score was calculated with only those items for which values existed.  A change was 
considered as clinically relevant when it was 10 points or more.The HRQoL scales endpoints that 
were preselected for this study are global health status, self-perceived cognitive functioning and 
pain; with the global health status scale as the primary HRQoL outcome for this study. 
Neuro-cognitive assessment: For each of the 6 standardized psychometric test outcomes, for each 
patient and for each time-point, the reported test scores were converted to raw scores. (18) For each 
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time-point, the tests raw scores were normalized into z-scores using at baseline the patient’s age 
(HVLT-R and Trail Making Test) or gender (COWA). The change from baseline in z-scores s calculated 
as z-score at post-baseline time-point minus z-score at baseline. The HVLT-R test scores were 
adjusted according to the patient’s age. The score at the last assessment after baseline with 60% 
compliance was computed and compared between treatment arms by Wilcoxon rank sum test. To 
account for multiplicity the Hochberg Step Up Procedure was applied at an overall 5 % significance. 
The Reliable Change Index (RCI) was calculated for each test in order to define neurocognitive failure. 
This was defined for each of the 6 NCF test outcomes as a change in a raw score that exceeds the RCI 
calculated as ±1.64 (SEdiff), where SEdiff = [2SEM2]1/2 and SEM = SD1[1-rxy]1/2. 
Neurological Deterioration was defined as a decrease in WHO performance status:  for patients with 
baseline WHO performance status 0 or 1 deterioration to WHO performance status 2 or worse for 
which no other explanation is present, and which is maintained for at least 3 weeks; for patients with 
baseline WHO performance status 2 deterioration to WHO performance status 3 or worse for which 
no other explanation is present and which is maintained for at least 3 weeks. Adverse events were 
scored according to the NCI-CTCAE version 4 criteria.Central MR assessment: All MRI were centrally 
reviewed centrally according to the RANO criteria by either MvdB or MS, the reviewers were blinded 
to treatment allocation. Images were coded and collected centrally at EORTC HQ, and then 
transferred on a hard disk for review.  
 
 
Organization of the trial, role of the funding source 
The trial was developed by the principal investigator (MvdB) in collaboration with the leading 
investigators for neuroimaging (MS), molecular analysis (PF), neurocognition (MK) and health-related 
quality of life (MT, JR) as well as the EORTC Headquarters (TG, CC). All data have been reviewed by 
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EORTC Headquarter staff and MvdB, PF, JR, MT and MK where appropriate. Statistical analyses were 
performed by TG and CC. Translational research and molecular marker evaluation was coordinated 
by PF. Central imaging review was conducted by MS and MvdB. The corresponding author had full 
access to all of the data and the final responsibility to submit for publication. The trial sponsor was 
the EORTC. The trial was supported by an unrestricted educational grant and free bevacizumab 
supply by Hoffmann La Roche. The drug manufacturer was not involved in trial design or analysis. The 
study was registered at EudraCT# 2009-017422-39 and ClinicalTrials.gov NCT01164189. The protocol 
was approved by the ethics committees and competent authorities of all participating centers and 
countries. All patients gave written informed consent for trial participation, pathology review and 
molecular testing.  The full study protocol can be reviewed at 
h�p://www.eortc.be/services/doc/protocols/26091v2.0.pdf 
 
  
Results 
Between 8/2/2011 and study closure on 31/7/2015 for enrollment completion, 155 patients were 
randomized; the final database lock was on  10/01/2017. Median age was 44 years, 101 (65%) of 131 
tested tumors showed an IDHmt, 42 (27%) of patients had received prior chemotherapy. Patient 
characteristics were well balanced between treatment arms (table 1); figure 1 shows the CONSORT 
diagram of this study. At review, 12 patients (8 in the combination arm) were considered to not fully 
meet the entry criteria (inadequate baseline MR imaging (7); hypertension (1); no target lesion (3); 
and 2nd recurrence (1)). At central pathology review of tissue from the first diagnosis, 11 patients in 
both arms were considered to have had a glioblastoma. Of those 22 patients, 10 were IDHmt and 2 
were IDH status undetermined. Four patients never started treatment. The median number of 
temozolomide cycles in the temozolomide monotherapy arm was 7 and in the combination arm 8. 
The median number of bevacizumab cycles (4 weeks) in the combination arm was 8.  The 
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temozolomide RDI in the single agent arm was 98%, in the combination arm 91%.  The RDI of 
bevacizumab was 94%. In 88 (57%) of patients, temozolomide was discontinued because of 
progression, in 34 (22%) because of the completion of 12 cycles and in 16 (10%) for toxicity . 
Bevacizumab was discontinued in 49 (63%) patients for progression, in 12 (15%) for toxicity, in 10 for 
other reasons; treatment was ongoing in 5 patients at the time of database lock. 
Safety and tolerability  
In the safety population, 37 of the 75 (49%) patients the monotherapy arm and 44 of the 76 (58%) 
patients in the combination arm had at least one dosage of temozolomide delayed. Forty-two 
patients (55%) had at least one cycle of bevacizumab delayed.  The most frequent toxicity was 
hematological: 17 (23%) patients in the monotherapy arm and 25 (33%) in the combination arm 
developed grade 3 or 4 hematological toxicity ( table 2)). In 17 patients (23%) treated with 
temozolomide alone and in 44 patients (58%) in the combination arm grade 3 of 4 adverse events 
were reported. Table 3 presen t  other grade 1-2 adverse events occurring in ≥ 10% of patients and 
grade 3, 4 and 5 adverse events. There were 8 serious adverse events in  the monotherapy arm 
(hematological: 2, hematological complicated by infection: 2, seizures:2, infection:1) and 39 in the 
combination arm (hematological:6, hematological complicated by infection: 2, seizures: 5, 
pulomonary embolism: 3, allergic reactions: 4, infections: 7). One patient in the combination arm 
died from a pulmonary infection after suffering from an intratumoral bleed during a related grade IV 
thrombocytopenia. 
 
Outcome: survival analysis 
At the time of analysis median follow-up was 28 months (interquartile range: 20.6 months), 135 
patients (87%) had progressed and 24 patients (15%) were still alive. At one year 44 of the 72 eligible 
temozolomide patients (61% [53,69]) and 38 of the 69 (55% [47,69]) eligible combination arm 
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patients were alive. Median survival in this group was 14.8 month (12.9,16.9) in the temozolomide 
arm and 12.9 months (10.6,16.3) in the combination arm; after 2 years respectively 25.2% (14.9,36.9) 
and 23.5% (13.7,34.8) of patients were still alive. Median progression free survival in the eligible 
patient population was 6.3 months (5.5,8.5) in the temozolomide arm and 5.9 (5.6,8.2)in the 
combination arm. In temozolomide arm, the 6 mo NDFS was 80.0% (67.9, 87.9) and the median not 
reached. In the combination arm, the 6 mo NDFS  was 82.5% (70.6, 89.9) and median 11.3 mo (8.8 , 
22.1). Table 4 and figure 2 a and b present the Kaplan Meier analysis of PFS and OS in the intent to 
treat population. A total of 141 patients were evaluable for response (temozolomide arm: 72; 
temozolomide plus bevacizumab: 69). In the temozolomide only arm 32 of 77 patients had an 
objective response rate  by central review (44.4%; 32.7,56.6) and 34 of 69 patients (52.2%; 39.8,64.4) 
in the combination arm. The duration of response was similar in both arms (temozolomide arm: 5.7 
months, 95% CI [3.0, 8.6]; temozolomide plus bevacizumab 5.6 months, 95% CI [3.0, 5.9].  In the Cox 
model, the treatment effect was not statistically significant (HR 1.11(0.77-1.60), p=0.59), only the 
performance status at baseline was associated with outcome (PS 2: HR 3.86, [2.22, 6.72, p<0.0001] 
Prior chemotherapy (data not shown) and grade (HR 1.31(0.89,1.92), p=0.17) did not impact OS.  
In the supplementary files page 2 - 4 treatment after progression following protocol therapy is 
shown.  In the temozolomide arm 50 (79%) patients received some type of chemotherapy and 22 
(33%) bevacizumab; in the combination arm 41 (59%) received some type of chemotherapy and 12 
(17%) continued or were retreated with bevacizumab.  
Outcome: analyses of neurocognitive functioning and HRQoL 
At baseline 142:155 patients were assessed with neurocognitive testing (compliance 92% (). With 25 
of 40 progression free tested patients tested at week 60 , the compliance with the neurocognitive 
testing remained above 60% up to that week (supplementary file table 2, page 5). There was no 
difference in compliance between both study arms at any time points. Neither at the last test 
available before or at week 60 or at longitudinal analysis during follow-up statistically significant 
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differences were observed between the study arms in any of the six test outcomes  (Supplemental 
file fig 1 page 7: trail making B). 
At baseline HRQoL forms were received from 145 patients (94%), with 26 of 40 progression free 
tested patients at week 60 the compliance with HRQoL forms remained above 60% up to that time 
point (supplementary table 2, page 5). There was no significant difference in compliance between 
both study arms. The global health status was similar in both arms throughout the follow-up (p = 
0.26; figure 3), self-reported neurocognitive functioning and the pain scale also showed no difference 
between the two treatment arms (suppl file figure 2 and 3 page 8, 9) 
Molecular analysis 
In 125 patients sufficient material was available for methylation arrays. There was a trend towards 
worse OS in the patients with material available for this analysis compared to the 30 without 
material for analysis (p = 0.07). Four patients were diagnosed as 1p/19q co-deleted by methylation 
array (two in each study arm), they had been locally diagnosed as non-codeleted, all had 
oligodendroglial histology. Of these 125 cases, 92 had IDH mutations and 26 were IDHwt (7 missing),  
91 were considered MGMT promoter methylated. Of the 92 IDHmt tumors with available MGMT 
status, 77 (83.6%) were considered MGMT methylated. The presence or absence of an IDH mutation 
was not associated with any trend towards benefit of adding bevacizumab (IDH mutated (HR 0.94, 
(0.59, 1.49); IDHwt population HR 1.46, (0.68, 3.07); interaction test p=0.33). The 6 mo PFS in MGMT 
promoter methylated patients was 59.3%(48.5,68.6), in unmethylated 29.4% (15.4,45.0), HR 0.47 
(0.31, 0.72)   
 
Prognostic and predictive factor analysis 
In the absence of an improved outcome in the combination arm, in an exploratory analysis we 
analysed both treatment arms together. Sex, age, surgery at recurrence, prior chemotherapy, frontal 
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involvement, tumor grade at initial surgery did not have any prognostic value. Median survival in 
initially as grade II diagnosed tumors was similar to initially grade III tumors: 14.5 months (12.6-16.6) 
versus 14.8 months (11.3-17.8), p = 0.64, supplemental file page 10 figure 4a). In contrast, MGMT 
status,  IDH status (median OS IDHwt patients 10.1 months versus IDHmt patients 15.2 months, p < 
0.001; supplemental page 10 fig 4b), performance status, use of steroids, number of target lesions, 
size of the lesion at recurrence and time since initial surgery had statistically significant correlations 
with OS. In multivariate analysis including both MGMT and IDH, both were independent factors 
associated with OS (IDHmt: HR 0.50 0.31, 0.80) p = 0.004;  and MGMTmeth HR 0.48 (0.31, 0.76), p = 
0.002);  bootstrapping included MGMT in 77% and IDHmt in 58% of the models. In multivariate 
analysis using both clinical and molecular factors, lesion maximum diameter (p=0.0002), 
performance status 2 (p<0.0001), MGMT (p=0.002) and IDH status (p=0.003) were identified as 
factors of independent prognostic significance. (C-index 68%). All were confirmed with bootstrapping 
(inclusion probability MGMT 80%, IDH 72% ). Corticosteroids use was predictive for benefit to 
temozolomide monotherapy (interaction test, p = 0.014). In exploratory analysis, no subgroup 
benefitting from adding bevacizumab to temozolomide could be identified (supplemental files figure 
5 page 10-14). 
  
Discussion 
Similar to the initial trials in glioblastoma, initial uncontrolled series suggested a benefit of 
bevacizumab in relapsing astrocytoma and oligodendroglioma. (6-9) This study on 155 recurrent 
WHO grade II and III glioma patients without 1p/19q co-deletion treated at first and enhancing 
recurrence however did not show any indication of an improvement in outcome with the addition of 
bevacizumab to temozolomide. Moreover, we did also not see an improved response rate in the 
combination arm, and taken together this appears to exclude a relevant role of VEGF signaling in this 
disease. We selected patients with an enhancing recurrence, in which neo-angiogenesis is more likely 
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to have developed and histology is likely to resemble glioblastoma. Whether there is still a role for 
bevacizumab as an anti-edema agent in late-stage disease and in palliative setting of relapsing 
astrocytoma patients cannot be answered by this trial, but a significant anti-tumor effect can be 
ruled out. At the time of analysis 12 patients were judged ineligible at medical review, predominantly 
because of absence of measurable disease and 4 patients did not start the allocated treatment. 
Nonetheless, even if 3 more eligible patients would have been present in the combination arm and 
they would all have survived at one year, the primary endpoint would still not have been met. 
Moreover, the PFS and OS analysis in both the eligible patient population and the intent to treat 
patient population failed to show any evidence of improved outcome in the combination arm when 
considering the temozolomide monotherapy arm.  
Bevacizumab has now been registered for use in glioblastoma for its beneficial effect on PFS and the 
reduction of steroid use. The results of the TAVAREC trial are different: no PFS improvement was 
observed  which raises the question whether VEGF signaling is less relevant in dedifferentiated grade 
II and III glioma as compared to glioblastoma.  Moreover, despite the anti-edema effects of 
bevacizumab in glioblastoma and presumed effects on neurological functioning of patients, no 
difference was observed in the quality of life nor in the neurocognitive functioning of patients. We 
have no evidence that bevacizumab improved the functioning of patients, and since in this study PFS 
was similar in both arms there is no impact of duration of treatment on the analysis allowing a 
proper assessment of the impact of bevacizumab on patient functioning.  One difference between 
this trial and the trials on recurrent glioblastoma is the less frequent use of steroids at baseline in the 
anaplastic glioma patient population at first recurrence.  
The most relevant limitation of this study is that it is a randomized phase II study, not powered for 
formal comparison. It is however still the largest randomized trial on recurrent astrocytoma since the 
pivotal temozolomide randomized phase II registration trial.(2) Also, the treatment approach to this 
disease is variable, with different strategies early on in the disease which impact treatment at 
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progression. To have a more homogeneous patient population we did not allow 1p/19q co-deleted 
tumors, although four co-deleted tumors were identified afterwards as part of the molecular studies. 
Importantly, the current study confirmed our expectation at the time of the study design that tumor 
grade (grade II or grade III) at initial diagnosis does not impact OS once an enhancing recurrence 
develops, but clearly IDH mutational status does. Since IDHwt and IDHmt glioma present different 
diseases, they should be kept separate in future studies, but tumor grade (grade II versus grade III) is 
irrelevant in this setting. We were in particular interested whether we could identify molecular 
factors that would allow the selection of patients that were unlikely to benefit from temozolomide. 
As expected,  MGMT promoter methylation and IDH status were highly correlated and both were 
correlated with survival. In glioblastoma, the absence of MGMT promoter methylation has been 
found to be associated with a very poor outcome to 2nd line chemotherapy.(17;25) In this dataset, 
the 6 mo PFS was still 29% in patients with MGMT unmethylated tumors, which implies that in these 
tumors absence of MGMT methylation cannot be used as a reliable criterion for a decision to 
withhold chemotherapy at the time of progression.  
To conclude, in WHO grade II and III 1p/19q intact relapsing glioma, the addition of bevacizumab to 
temozolomide does not improve survival or quality of survival. Future trials on 1p/19q intact glioma 
can combine grade II and III tumors, but should distinguish between IDHmt and IDHwt tumors. 
 
For an overview of participating sites, principal investigator and accrual per site, see supplemental 
file table 3, page 6. 
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Figure 1. CONSORT flow diagram 
Figure 2A: Progression Free survival in the intent to treat population 
Figure 2B. Overall survival in the intent to treat population 
Supplemental file 1. Forest plot of known and potential major clinical and molecular prognostic 
factors.
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Table 1 Baseline characteristics at randomization 
 
TMZ 
(N=77) 
TMZ+Bv 
(N=78) 
 
 N (%) N (%) N (%) 
Sex: male    45 (58.4)                                                                                            57 (73.1)                                                                         102 (65.8)                              
Median age at randomization (years)                                                                                                                                                                                                                                                                                                                                                                           43.1 44.6 43.3
Prior chemotherapy given                                                                                                                                                                                                                                                                                                      
 no                                                                                                                                             56 (72.7)                                                                                57 (73.1)                                                                         113 (72.9)                              
 TMZ (Concomitant and/or Adjuvant = one line)                                                                                            21 (27.3)                                            16 (20.5)                                                                        37 (23.9)                                                
 PCV                                                                                                                                        0 (0.0)                                                                                 5 (6.4)                                                                                   5 (3.2)                           
WHO grade at first (local) diagnosis                                                                                                        
 Grade II                         40 (51.9)                                                                                            43 (55.1)                              83 (53.5)                            
 Grade III                        36 (46.8)                                                                                            34 (43.6)                                                                        70 (45.2)                            
 Missing                           1 (1.3)                                                                                          1 (1.3)                                                                                     (1.3)                        
WHO performance status                                                                                                                                                                                                                                                                              
 0                                                                                                                                            34 (44.2)                                                                                31 (39.7)                           65 (41.9)                           
 1                                                                                                                                            35 (45.5)                                                                                38 (48.7)                                                  73 (47.1)                            
 2                                                                                                                                               8 (10.4)                                                                                9 (11.5)                                                                                   17 (11.0)                            
Prior irradiation given                                                                                                                                                                                                                                                                                                                   
 no                                                                                                                                                                                                      2 (2.6)                                                                                           5 (6.4)                                            7 (4.5)                           
 Yes   75 (97.4)                                                                                            73 (93.6)                                                                         148 (95.5)                              
Surgery at the time of progression                                                                                                                                                                                                                             
 yes                                                                                                                                                                                                        22 (28.6)                                                                                         24 (30.8)                           46 (29.7)                            
Corticosteroids intake                                                                                                                                                                                                                                                                                                             
 Yes   27 (35.1)                                                                                            22 (28.2)                                                                              49 (31.6)                                   
Time since last radiotherapy (months)                                                                                                                                                                                 
 Median                                                                                                                                                                                                  29.3 28.1 28.7
 Range                                                                                                                                                                                                   3.6 - 177.1 4.2 - 239.6        3.6 - 239.6
MGMT                                                                                                                          
 Unmethylated                     12 (15.6)                                                                                            22 (28.2)                                                                        34 (21.9)                                      
 Methylated                       51 (66.2)                                                                                            40 (51.3)                                                                        91 (58.7)                            
 Not determinable                 14 (18.2)                                                                                            16 (20.5)                              30 (19.4)                            
IDH                                                                                                                                   
 Wildtype                         14 (18.2)                                                                                            16 (20.5)                                               30 (19.4)                            
 Mutated                          53 (68.8)                                                                                            48 (61.5)                                                                          101 (65.2)                                                       
 Undetermined                     10 (13.0)                                                                                            14 (17.9)                                                                         24 (15.5)                                                   
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Table 2. Hematological toxicity in the safety population 
 Temozolomide 
 (n = 75) 
 Temozolomide and Bevacizumab 
(n = 76) 
Hematological toxicity   Grade 2 Grade 3 Grade 4 Grade 2 Grade 3 Grade 4 
 ANC 6 (8%) 3 (4%) 3 (4%) 10 (13%) 6 (8%) 5 (7%) 
 WBC 7 (9%) 2 (3%) 1 (1%) 16 (21%) 3 (4%) 2 (3%) 
 platelets 8 (11%) 3 (4%) 5 (7%) 13 (17%) 6 (8%) 7 (9%) 
 lymphocytes 21 (28%) 3 (4%) 5 (7%) 25 (33%) 12 (16%) 1 (1%) 
 hemoglobin 1 (1%) 2 (3%) 0 2 (3%) 0 0 
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Table 3. Adverse events  (worst grade)per patient  adverse events per treatment arm in the safety population. 
 TEMOZOLOMIDE (n = 75) TEMOZOLOMIDE + BEVACIZUMAB (n = 76) 
ADVERSE EVENT Grade 0 Grade 1-2 Grade 3 Grade 4 Grade 0 Grade 1-2 Grade 3 Grade 4 Grade 5 
BIOCHEMISTRY          
 SGPT/ALAT 38 32 (43%) 3 (4%) 0 39 35 (46%) 2 (3%) 0 0 
 HYPOCALCEMIA 63 7 (9%) 2 (3%) 0 64 4 (5%) 6 (8%) 1 (1%) 1 (1%) 
 HYPONATREMIA 67 6 (8%) 0 0 65 3 (4%) 8 (11%) 0 0 
 HYPERKALEMIA  66 2 (3%) 6 (8%) 0 50 2 (3%) 23 (30%) 0 1 (1%) 
FEBRILE NEUTROPENIA 74 0 1 (1%) 0 76 0 0 0 0 
VENTRICULAR DYSFUNCTION 75 0 0 0 75  0. 1(1%) 0 0 
VOMITING 55 20 (27%) 0 0 55 19 (25%) 2 (3%) 0 0 
CONSTIPATION 48 27 (36%) 0 0 46 30 (39% 0 0 0 
DIARRHOEA 69 6 (8%) 0 0 62 12(16%) 2 (3%) 0 0 
NAUSEA 36 39 (52%) 0 0 33 42 (55%) 1 (1%) 0 0 
PANCREATITIS 75 0 0 0 75 0 1 (1%) 0 0 
WEIGHT DECREASED 69 6 (8%) 0 0 59 16 (21%) 1 (1%) 0 0 
WEIGHT INCREASED 59 16 (21%) 0 0 57 17 (22%) 2 (3%) 0 0 
FATIGUE 22 52 (69%) 1 (1%)  15 54 (71%) 7 (9%) 0 0 
HEPATIC FAILURE 74 0 1 (1%) 0 76 0 0 0 0 
ANAPHYLACTIC REACTION 75 0 0 0 75 0 1 0 0 
HYPERSENSITIVITY 72 3 (4%) 0 0 71 2 (3%) 3 (4%) 0 0 
INFECTIONS (ALL) 58  15 (20%) 2 (3%) 0. 47 18 (24%) 10 (13%) 0 1 (1%) 
WOUND DEHISCENCE 74 0 1 0 75 1 0 0 0 
HYPERGLYCEMIA 73 1 (1%) 0 1 (1%) 75 0 1 (1%) 0 0 
NERVOUS SYSTEM DISORDERS   16  49 (65%) 10 (13%) 0 11 48 (63%) 15 (20%) 2 (3%) 0 
SEIZURES 42 28 (37%) 5 (7%) 0 41 27 (36%) 7 (9%) 1 (1%) 0 
PROTEINURIA 75 0 0 0 68 7 (9%) 1 (1%) 0 0 
COUGH 71 4 (5%) 0 0 68 8 (11%) 0. 0 0 
DYSPHONIA 74 1 (1%) 0 0 67 9 (12%) 0 0 0 
EPISTAXIS 74 1 (1%) 0 0 68 8 (11%) 0 0 0 
RASH  69 6 (8%) 0 0 64 8 (11%) 4 (5%) 0 0 
SKIN ULCER 75 0 0 0 75 0 1 (1%) 0 0 
EMBOLISM 75 0 0 0 75 0 1 (1%) 0 0 
HYPERTENSION 61 13 (17%) 1 (1%) 0 39 27 (36%) 10 (13%) 0 0 
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Table 4. Progression free and overall survival in the intent to treat population ( in bold: % 12 months 
(mo) overall survival in the intent to treat population) 
 Progression free survival Overall survival 
 Median  6 mo  12 mo  Median  12 mo 24 mo 
Temozolomide 6.1 mo 50.0% 30.3% 15.0 mo 63.1% 26.8% 
temozolomide/bevacizumab 6.9 mo 53.9% 27.6 13.8 mo 59.8% 26.2% 
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